EP0188555A1 - Yeast cloning vehicle - Google Patents
Yeast cloning vehicleInfo
- Publication number
- EP0188555A1 EP0188555A1 EP85903625A EP85903625A EP0188555A1 EP 0188555 A1 EP0188555 A1 EP 0188555A1 EP 85903625 A EP85903625 A EP 85903625A EP 85903625 A EP85903625 A EP 85903625A EP 0188555 A1 EP0188555 A1 EP 0188555A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sequence
- yeast
- signal
- dna
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 97
- 238000010367 cloning Methods 0.000 title claims abstract description 36
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 87
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 62
- 239000012634 fragment Substances 0.000 claims abstract description 58
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 45
- 108020004414 DNA Proteins 0.000 claims abstract description 33
- 108091029865 Exogenous DNA Proteins 0.000 claims abstract description 31
- 150000001413 amino acids Chemical group 0.000 claims abstract description 25
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 9
- 230000035897 transcription Effects 0.000 claims abstract description 9
- 238000013518 transcription Methods 0.000 claims abstract description 9
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 8
- 230000007017 scission Effects 0.000 claims abstract description 8
- 230000003248 secreting effect Effects 0.000 claims abstract description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 87
- 239000013612 plasmid Substances 0.000 claims description 59
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 37
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 108010051457 Acid Phosphatase Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 210000000349 chromosome Anatomy 0.000 claims description 4
- 108091058545 Secretory proteins Proteins 0.000 claims description 3
- 102000040739 Secretory proteins Human genes 0.000 claims description 3
- 230000001254 nonsecretory effect Effects 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 2
- YAXNATKKPOWVCP-ZLUOBGJFSA-N Ala-Asn-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O YAXNATKKPOWVCP-ZLUOBGJFSA-N 0.000 claims 1
- 108091081024 Start codon Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 108091026890 Coding region Proteins 0.000 description 13
- 238000010276 construction Methods 0.000 description 9
- 230000004927 fusion Effects 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 230000004543 DNA replication Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 3
- 102000013563 Acid Phosphatase Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 101150108727 trpl gene Proteins 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 108010058643 Fungal Proteins Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710093417 Phosphate-repressible acid phosphatase Proteins 0.000 description 1
- 101710167911 Repressible acid phosphatase Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 1
- 230000001036 exonucleolytic effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000000063 preceeding effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Definitions
- This invention relates to cloning vehicles for production of proteins.
- proteins is used in this application to include peptides of indefinite size.
- proteins exported from eukaryotic cells are processed in a secretory pathway that involves synthesis of a precursor protein (containing an amino-terminal "signal" peptide region), translocation across endoplasmic reticulum membranes, followed by specific signal peptide cleavage and further processing including carbohydrate additions (glycosylation), and finally secretion of the mature product out of the cell.
- the yeast Saccharomyces cerevisiae is known to have such a secretory pathway [see Schekman and Novick, "The secretory process and yeast cell-surface assembly", in The Molecular Biology of the Yeast Saccharomyces: Metabolism and Gene Expression. Strathern et al. (Eds.), Cold Spring Harbor Laboratory. 1982]. Moreover, unlike an analogous secretory pathway that exists in some prokaryotic species, the yeast secretion mechanism provides components capable of glycosylating proteins. Hitzeman et al. (1983) Science 219:620-625 report expression and secretion in yeast of human interferon based on a coding region containing the interferon signal sequence. The mature secreted protein reported by Hitzeman et al.
- Hinnen et al. at an International Congress of Microbiology (Boston, Massachusetts 1982) reported the fusion of a DNA fragment from the PH05 gene of the yeast Saccharomyces cerevisiae (containing the promoter and 80% of the 5' end of the PH05 signal sequence) to a cDNA fragment coding for the mature protein sequence and a portion of the 3' end of the signal sequence of human alpha interferon.
- PH05 codes for the major repressible (by phosphate) acid phosphatase, a secreted enzyme in this yeast.
- This construction lacks the DNA coding sequence for the last 3 amino acids of the PH05 signal peptide and instead the last three amino acids of the hybrid signal are those coded for by the human cDNA sequence—i.e., the amino acids of the pre-interferon signal information.
- the plasmid constructed by Hinnen et al. was used to transform cells of Saccharomyces cerevisiae. The transformants were reported to express interferon activity under phosphate regulation. Localization of the interferon activity (intracellular versus extracellular) was not discussed. Summary of the Invention
- the invention features generally a cloning vehicle that is used to transform a microorganism for expression and secretion of a protein.
- the cloning vehicle includes, in order of transcription: a yeast transcription control DNA sequence, a DNA sequence coding for a yeast signal peptide and an exogenous DNA sequence coding for a desired protein.
- the invention features a DNA fragment which includes: a signal sequence substantially identical to a yeast PH05 transcription control sequence; a sequence coding for a signal peptide substantially identical to a complete PH05 signal peptide, and having the same three carboxy-terminal amino acids as a PH05 signal peptide; and a restriction endonuclease site adjacent to the carboxy terminal end of the signal sequence.
- the invention features a method of making the above-described plasmid by providing naturally occurring PH05 transcription control and signal sequences, and modifying them by creating a restriction endonuclease cleavage site at the 3' end of the signal sequence without changing the identity of the three carboxy-terminal amino acids encoded by the DNA signal sequence.
- the cloning vehicle containing the exogenous DNA sequence can be used to transform a yeast host, the transformed host is cultured, and secretion of the desired protein is obtained.
- yeast transcription control DNA sequence means a DNA sequence naturally occurring in yeast which is effective to initiate transcription of DNA.
- yeast signal DNA sequence means a DNA sequence which codes for a signal peptide sequence that naturally occurs in yeast.
- Exogenous DNA refers to DNA which is not naturally found associated with the yeast transcription control DNA sequence and the yeast signal DNA sequence of the vehicle of the invention.
- the transcription control DNA sequence is identical to the transcription control DNA sequence of a naturally occurring yeast gene, and the yeast signal DNA sequence codes for a peptide identical to a signal peptide produced by that gene.
- the yeast gene is the PH05 gene, which codes for the major repressible acid phosphatase enzyme.
- PH05 is contained within an 8-kilobase (kb) EcoRI region of the genomic DNA of chromosome 2 in Saccharomyces cerevisiae. Both the transcription control sequence and the adjacent signal DNA sequence of this gene are contained within a smaller 600-base pair (bp) BamHI-Kpnl portion of this region.
- the exogenous DNA can be yeast DNA coding for nonsecreted (or secreted) yeast proteins; however, preferably, the exogenous DNA sequence corresponds to a sequence coding for a nonyeast protein.
- the above described cloning vehicle enables expression of exogenous DNA in yeast, so that the protein product is secreted by the yeast into the surrounding medium.
- the protein is recovered in its mature form after processing (i.e., removal of the yeast signal sequence). Control over the placement and spacing of the signal sequence, as described below, will enable the desired exogenous protein to be expressed and processed by the host organism, such that cleavage of the signal sequence will occur at the correct site and the mature form of the protein will be secreted.
- the information necessary to effect the correct processing of the mature protein is contained in the yeast signal DNA sequence, and is not dependent on the nature of the DNA sequence coding for the exogenous protein.
- the above described cloning vector is useful for expression and secretion of DNA sequences coding for any secretory and nonsecretory exogenous proteins. Description of the Preferred Embodiment
- Figure 1 is a diagram representing plasmid 99NMlu-alpha.
- Figure 2 is a diagram representing plasmid 99N.
- Figure 3 is a diagram representing plasmid 99NMlu.
- Figure 4 is a diagram representing plasmid 99N-alpha.
- Figure 5 is a partial restriction map of a DNA fragment cloned into pBR322, including the coding sequence for the first 30 nucleotides of mature alpha HCG.
- Cloning Vehicle Structure The components of the cloning vector or vehicle are illustrated by plasmid 99NMlu-alpha, depicted in Fig. 1, and, alternatively, by p99N-alpha in Fig. 4.
- the plasmid includes a yeast transcription control sequence which comprises a functional promoter region and a transcription initiation site.
- the functional yeast promoter region should include sufficient sequences upstream from other plasmid components to permit initiation of transcription, for example, a complete naturally occurring yeast promoter. (Naturally occurring yeast transcription control DNA sequences containing certain deletions at the 3' end are also functional promoters.)
- the 5' to 3' DNA sequence from the BamHI site (-553) to the nucleotide preceding the ATG triplet (defined as +1, +2, +3), represents a functional PH05 promoter region with sufficient upstream sequences to permit initiaton of transcription. Certain deletions of the 3' end of the PH05 transcription control region are also functional promoters.
- Fused in phase with the transcription control sequence is a sequence which is transcribed and translated into the signal peptide of a yeast secretory protein.
- p99NMlu-alpha codes for a signal peptide (identical to the PH05 signal peptide), having the following amino acid sequence: Met-Phe-Lys-Ser-Val-ValTyr-Ser-Ile-Leu-Ala-Ala-Ser-Leu-Ala-Asn-Ala.
- the DNA sequence coding for the signal peptide on p99NMlu-alpha is: ATGTTTAAATCTGTTGTTTATTCAATTTTAGCCGCTTCTTTGGCCAACGCG, The above yeast DNA sequences are positioned in phase with the DNA sequences coding for the desired exogenous protein.
- "Exogenous protein” means a protein that, in naturally occurring systems, is not produced under control of the yeast promoter of the vehicle, and is not produced with the yeast signal peptide of the vehicle. This term includes yeast proteins, but preferably the exogenous DNA sequence codes for the mature form of a nonyeast protein.
- Changes can be made in naturally occurring signal DNA sequences to facilitate fusion of the signal sequence to the sequence coding for the mature protein, but one should avoid changes which are reflected in the amino acid sequence of the resulting signal peptide.
- the 3' end of the signal DNA sequence is ligated to the 5' end of the exogenous DNA sequence such that there are no extraneous nucleotides between the sequences. In this way, the nascent protein will contain a signal peptide directly adjacent to the desired mature protein and the protein that is secreted should not contain extraneous amino acids.
- plasmid p99N DNA replication origins and DNA fragments conferring phenotypic bases for plasmid selection.
- the detailed features which are present in p99NMlu-alpha are illustrated by the following description of its precursor, plasmid p99N, and of the method of making p99NMlu-alpha from p99N.
- the above-described cloning vehicle can be constructed by engineering a vector containing a yeast transcription control sequence and a yeast signal sequence which has been modified to provide a multipurpose cloning site.
- Plasmid 99NMlu (Fig. 3) is such a vector containing a cloning site Mlul.
- the restriction site should be positioned at or near the end of the yeast signal DNA sequence, so that any exogenous DNA sequence coding for a desired secretory or nonsecretory protein, which has been engineered by restriction digest or by the use of synthetic linkers, is then inserted into the Mlul site of plasmid 99NMlu, and expression and secretion of the desired protein or peptide is achieved.
- the linker used may be engineered to maintain the intact naturally occurring signal DNA sequence, but the redundancy of the genetic code provides some flexibility as to the engineering steps performed. Similarly, engineering and nucleotide additions may be required at the 5' end of the exogenous DNA sequence to insure an inphase fusion to the signal sequence.
- An example of the structure and construction of such linkers is outlined below for p99NMlu-alpha.
- Plasmid 99N includes the following DNA segments
- the functional TRPl gene from yeast contained within a 1.45 kb EcoRI genomic DNA fragment from chromosome 4. described in Kingsman et al. (1979) Gene 7 , 141-152 and in Tschumper and Carbon (1980) Gene 10. 157-166.
- This fragment contains a 103 bp functional TRPl promoter region, a 672 bp coding sequence, and a 678 bp 3' untranslated region, which functions not only as a transcription termination sequence but also as a weak DNA replication origin (or replicon) called the arsl sequence; plasmid YRp7 has been described by Tschumper and Carbon (1980) and consists of this 1.45 kb EcoRI fragment inserted into pBR322 at the EcoRI Site in an orientation such that TRPl and the gene for ampicillin resistance are transcribed in the same direction.
- HincI I fragment contains a "strong" origin of DNA replication, (i.e., “stronger” than arsl because it confers a higher plasmid copy number in yeast) and confers a much lower rate of plasmid loss per mitotic cell division. This is also partly due to the presence of endogenous 2-micron plasmids carried in most strains of yeast.
- the orientation of the vector fragment in plasmid 99N is not important for this function;
- PH05 promoter plus all of the DNA sequence necessary to encode the 17 amino acid signal peptide (including the initial methionine);
- the Kpnl-EcoRI fragment is used as a spacer region.
- the source and length of this fragment is not important for its use in plasmid 99N or its derivatives.
- the spacer region consists of PH05 structural sequences.
- Plasmid 99N is constructed as follows. Plasmid YRp7 is partially digested with EcoRI such that only one of the two EcoRI sites is cleaved. Most of the product of this digestion consists of 5.8 kb linearized YRp7 molecules. Approximately half of these linear molecules are cleaved at one EcoRI site while the other half are cleaved at the other EcoRI site. This mixture of linear molecules is separated from uncleaved circular molecules and from shorter linear molecules, arising by occasional cleavage of both EcoRI sites, by gel electrophoresis as described in Maniatis et al. (1982), followed by elution from the gel.
- the 5' protruding EcoRI ends are then filled in with dNTP's using DNA polymerase I (Klenow enzyme).
- DNA polymerase I Klenow enzyme
- the 5' EcoRI protruding ends can first be removed with a single-strand-specific 5' to 3' exonuclease.
- the flush-ended molecules thus generated are rejoined (circularized) with DNA ligase, which results in the loss of one of the EcoRI recognition sequences.
- the plasmid of interest, YRp7' which retains the EcoRI site adjacent to the TRP1 promoter, is identified by restriction mapping.
- the 1.45 kb HincII fragment from the yeast 2 micron plasmid is ligated into the Nrul site of YRp7'.
- the plasmid that is generated, YRp7'N is digested with both EcoRI and BamHI.
- the large fragment. 6.87 kb, which is isolated from the gel, is the vector fragment.
- the PH05 gene of Saccharomyces cerevisiae codes for the major phosphate-repressible acid phosphatase enzyme (APase). corresponding to the peptide called p60. and is contained within an 8 kb EcoRI genomic DNA fragment from chromosome 2 described in Bostian et al. (1980) PNAS 77. 4504-4508 and in Kramer and Andersen (1980) PNAS 77, 6541-6545.
- the PH05 fragment is prepared by digesting a plasmid carrying the 8 kb EcoRI PH05 region (e.g. pAP20, as described in Anderson. Thill and Kramer, Molec. Cell Biol. 3:562-569.
- the composition of the Kpnl-EcoRI spacer fragment is arbitrary.
- the spacer fragment consists of PH05 structural sequences beginning at the Kpnl site (at +94bp) and terminating at the Pstl site (at +1500 bp) to which had been added an EcoRI linker sequence.
- the fragment is combined with the PH05 fragment and the vector fragment into a circular plasmid with DNA ligase. This product is used to transform E. coli to ampicillin resistance. From this pool of transformants plasmid 99N is identified and plasmid DNA is prepared. Plasmid 99N has been deposited with the NRRL and bears accession number 15790.
- Plasmid 99N can be used to construct a cloning vehicle (for example p99Nalpha) for an exogenous DNA sequence beginning with a G as the first base pair using the technique described below in the section "Plasmid 99N-alpha". Alternatively, the insertion of a Mlul site in p99N would allow expression of exogenous DNA without regard to the identity of the initial base pair. Plasmid 99NMlu.
- the next step involves the replacement of the Kpnl site located next to the Ball site with an Mlul site.
- pAPP is digested with Kpnl and the 3' overhang is removed using T4 DNA polymerase.
- Synthetic Mlul linkers ACGCGT
- Bacterial transformants are checked for the presence of a Mlul site; such a plasmid, pAPPM. is isolated.
- pAPPM is digested with Mlul and synthetic
- Construction of 99NMlu from plasmids 99N and pPhoM then is accomplished as follows: The 1.95kb BamHI-EcoRI fragment of pPhoM is isolated and ligated into 99N which has been cut with both BamHI and EcoRI and treated with bacterial acid phosphatase. Bacterial transformants are screened for plasmids having an Mlul site. Such a plasmid, 99NMlu, described in Figure 3. is isolated and can be used for fusions of the PH05 signal to foreign proteins. Plasmid 99NMlu has been deposited with the NRRL and bears accession number B 15792.
- alpha hCG human chorionic gonadotropin
- Saccharomyces cerevisiae directed by the promoter, translation initiation site and signal sequence of PH05.
- Both alpha hCG and yeast acid phosphatase are secretory proteins derived from pre-proteins containing a signal peptide at their amino terminal end.
- the first 50 nucleotides of the coding sequence of the mature alpha hCG contain no recognition sequences for any known restriction enzymes. A fusion of the mature portion of alpha hCG to any signal sequence would thus require the extensive use of very long synthetic DNA linkers.
- the DNA fragment coding for the mature form of alpha hCG can be engineered so that a correct in-phase fusion to the PH05 signal in plasmid 99NMlu can be achieved.
- Exonuclease Bal31 can be used to resect this fragment from the BamHI site under conditions in which about 90 bp will be digested.
- EcoRI linkers which contain a C at their 3' end can be ligated. Only molecules in which the resection had ended exactly at the sequence 5'TGCAG3' will - after addition of a C - contain a Pstl site at postion 94.
- the above mentioned ligation mixture can be cut with Pstl and fragments of about 250bp length which contain a Pstl site at each end can be selected by cloning into the Pstl site of pBR322. Plasmids containing such a fragment can be digested with Pstl and synthetic 10-mers (5'CATCAGGAGC3') and 18-mers
- the 3' fragment of the alpha hCG coding region can be inserted into this plasmid as a Xbal-EcoRI fragment and the entire BamHI-EcoRI fragment containing the PH05 promoter and the PH05 signal fused to the mature alpha hCG coding region can be inserted into p99NMlu to yield p99NMlualpha which then can be used to transform yeast. Plasmid 99N-alpha.
- plasmid 99N was used as a vector for constructing a hybrid gene in which the PH05 signal sequence was fused to the DNA sequence coding for the mature form of alpha hCG to yield plasmid 99N-alpha, illustrated in Fig. 4.
- the specific construction of the hybrid gene was possible because the PH05 signal sequence was manipulated to contain only the first 51 nucleotides, coding for the entire 17 amino acid signal peptide, plus an additional guanine (G) residue. This was achieved by first digesting the PH05 DNA with Kpnl enzyme to generate a 3' protruding strand. Then, flush ended molecules were obtained by the 3'-5' exonucleolytic activity of T4 DNA polymerase.
- the coding region of the mature alpha hCG was manipulated in a similar way as described above for making p99NMlu-alpha.
- Addition of a GA to the mature coding region creates a new restriction site Sad with the recognition sequence GAGCTC. This has been achieved by Iigating alpha-hCG fragments which had been resected with Bal31 from the BamHI site to fragments that contained a filled in Sall site and therefore a GA at their ends.
- the newly created Sad site contains within it an Alul site (AGCT). Cutting with Alul yields fragments which have the first G of the first amino acid of the mature alpha-hCG missing.
- Plasmid 99N-alpha has been deposited with the
- the cloning vehicle is used to transform a host yeast organism using standard techniques such as described by Beggs, Nature 275:104-109 (1978).
- the transformed yeast organism is cultured in a standard culture medium using standard techniques such as those summarized by Botstein and Davis "Principles and Practice of Recombinant DNA Research with Yeast", in The Molecular Biology of the Yeast Saccharomyces:
- Plasmid 99N-alpha was used to transform a strain of Saccharomyces cerevisiae carrying a mutant trpl gene (causing tryptophan auxotrophy) to the Trp+ phenotype (tryptophan prototrophy). Plasmid 99N-alpha carries an expressible yeast trpl gene allowing the transformed yeast to grow in the absence of tryptophan (Trp prototrophy). Suitable methods for the transformation of yeast by plasmid DNA are described for example by Beggs, 1978. One or more Trp transformants were isolated by single-colony isolation on synthetic growth medium lacking tryptophan. This S -TRP and is described in Table 1.
- the transformed strain was incubated in a low-phosphate synthetic liquid growth medium that lacks tryptophan and contains 30 mg/l KH 2 PO 4 and 1.5 g/1 KCl.
- This medium is called LP (SC--TRP) and is described in Table 1.
- Cells retaining the expression of plasmid 99N-alpha grow in this medium and begin to synthesize alpha hCG when the intracellular level of inorganic phosphate begins to decrease. After two days of incubation at 30 degrees C, virtually all (greater than 90%) of the antigenically active alpha hCG was found in the culture medium. Typical levels were 0.2 mg/1 or greater, as determined by radioimmunoassay.
- the yeast cells were at first removed from the harvested cell suspension by any of several convenient means such as centrifugation, filtration, etc. Then, the cell-free fermentation broth was subjected to appropriate protein purification procedures designed to isolate pure alpha hCG.
- plasmid 99NMlu can be used to attach the PH05 signal sequence to any foreign gene or cDNA and can be introduced to any strain of Saccharomyces cerevisiae.
- the transformed yeast can then be used to produce the desired foreign protein using techniques such as those described above for production of alpha hCG using yeast transformed with p99N alpha.
- the system provides an increased yield of the foreign protein which is secreted into the extra cellular fluid.
- the three terminal amino acids should be identical to the naturally occurring yeast signal sequence amino acids. While it is desirable to produce an intact, unmodified signal peptide, one-skilled in the art may be able to use the claimed invention while making a few such changes. Similarly, one may include a few extraneous amino acids at the N-terminal end of the desired polypeptide and tolerate some slight (3-6 base pairs) movement of the restriction enzyme site with respect to the end of the signal DNA sequence. What is claimed is:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Véhicule de clonage avec une séquence de régulation de transcription de levure et une séquence de signal de levure placée dans un cadre de lecture et une direction de transcription corrects par rapport à une séquence d'ADN exogène codant pour une protéine désirée. Dans un aspect particulier, les séquences de transcription et de signal sont essentiellement identiques à celles du gène PH05 naturel et la séquence de signal code pour un peptide de signal possédant les mêmes trois acides aminés terminaux carboxy que le peptide de signal PH05. Le véhicule est utilisé pour transformer une levure hôte sécrétant la protéine désirée. Il peut être préparé par la ligature de l'ADN exogène à un fragment d'ADN comportant un site de clivage d'endonucléase de restriction qui a été inséré à l'extrémité 3' de la séquence de signal, sans paires de bases étrangères entre eux; alternativement, lorsque G peut être la paire de base terminale 5' de l'ADN exogène, le véhicule peut être préparé par la ligature de l'ADN exogène, moins la base à son extrémité 5' à un fragment d'ADN où une seule base G a été placée entre l'extrémité 3' de la séquence de signal et la séquence d'ADN exogène.Cloning vehicle with a yeast transcription regulatory sequence and a yeast signal sequence placed in a correct reading frame and transcription direction relative to an exogenous DNA sequence encoding a desired protein. In a particular aspect, the transcription and signal sequences are essentially identical to those of the natural PH05 gene and the signal sequence codes for a signal peptide having the same three carboxy terminal amino acids as the signal peptide PH05. The vehicle is used to transform a host yeast secreting the desired protein. It can be prepared by ligation of exogenous DNA to a DNA fragment having a restriction endonuclease cleavage site which has been inserted at the 3 'end of the signal sequence, without foreign base pairs between them; alternatively, when G can be the 5 'terminal base pair of exogenous DNA, the vehicle can be prepared by ligation of exogenous DNA, minus the base at its 5' end to a DNA fragment where only one base G was placed between the 3 'end of the signal sequence and the exogenous DNA sequence.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62920384A | 1984-07-09 | 1984-07-09 | |
US629203 | 2000-07-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0188555A1 true EP0188555A1 (en) | 1986-07-30 |
EP0188555A4 EP0188555A4 (en) | 1988-04-18 |
Family
ID=24522022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19850903625 Withdrawn EP0188555A4 (en) | 1984-07-09 | 1985-07-09 | Yeast cloning vehicle. |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0188555A4 (en) |
JP (1) | JPS61502655A (en) |
DK (1) | DK103886A (en) |
WO (1) | WO1986000637A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0170266B1 (en) * | 1984-07-30 | 1993-03-24 | Wakunaga Seiyaku Kabushiki Kaisha | Process for producing protein, and vector, recombinant dna and transformant used therefor |
US5521086A (en) * | 1993-09-16 | 1996-05-28 | Cephalon, Inc. | Secretion sequence for the production of a heterologous protein in yeast |
CA2644926A1 (en) | 2006-03-06 | 2007-09-13 | Humagene, Inc. | A method for the preparation of recombinant human thrombin and fibrinogen |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0116201A1 (en) * | 1983-01-12 | 1984-08-22 | Chiron Corporation | Secretory expression in eukaryotes |
EP0143081A2 (en) * | 1983-11-21 | 1985-05-29 | Ciba-Geigy Ag | Synthesis of tissue plasminogen activator(TPA) by yeast |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2125047B (en) * | 1982-08-09 | 1986-02-19 | Ciba Geigy Ag | Yeast hybrid vectors and their use for the production of polypeptides |
-
1985
- 1985-07-09 JP JP50324385A patent/JPS61502655A/en active Pending
- 1985-07-09 WO PCT/US1985/001306 patent/WO1986000637A1/en not_active Application Discontinuation
- 1985-07-09 EP EP19850903625 patent/EP0188555A4/en not_active Withdrawn
-
1986
- 1986-03-07 DK DK103886A patent/DK103886A/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0116201A1 (en) * | 1983-01-12 | 1984-08-22 | Chiron Corporation | Secretory expression in eukaryotes |
EP0143081A2 (en) * | 1983-11-21 | 1985-05-29 | Ciba-Geigy Ag | Synthesis of tissue plasminogen activator(TPA) by yeast |
Non-Patent Citations (1)
Title |
---|
See also references of WO8600637A1 * |
Also Published As
Publication number | Publication date |
---|---|
JPS61502655A (en) | 1986-11-20 |
DK103886A (en) | 1986-05-07 |
EP0188555A4 (en) | 1988-04-18 |
DK103886D0 (en) | 1986-03-07 |
WO1986000637A1 (en) | 1986-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4588684A (en) | a-Factor and its processing signals | |
JP2572952B2 (en) | Method for producing a heterologous protein by a host using a substituted promoter | |
JP2793215B2 (en) | Improved expression and secretion of heterologous proteins in yeast using truncated .ALPHA.-factor leader sequences | |
US5037743A (en) | BAR1 secretion signal | |
US6642029B1 (en) | Hybrid DNA synthesis of mature insulin-like growth factors | |
JP3092811B2 (en) | Peptide and DNA sequences | |
US5789234A (en) | Expression systems for amidating enzyme | |
US6500645B1 (en) | N-terminally extended proteins expressed in yeast | |
CA1340837C (en) | Expression and secretion of heterologous proteins by yarrowia lipolytica transformants | |
EP0123544A2 (en) | Process for expressing heterologous protein in yeast, expression vehicles and yeast organisms therefor | |
US5100784A (en) | Process for the preparation of mature human serum albumin | |
EP0563175A1 (en) | A method of constructing synthetic leader sequences | |
WO1984004330A1 (en) | Secretion of exogenous polypeptides from yeast | |
JPS62228284A (en) | Yeast secretion vector | |
JP4187796B2 (en) | N-terminal extension protein expressed in yeast | |
JP4180112B2 (en) | Vector for expression of N-terminally extended protein in yeast cells | |
EP0188555A1 (en) | Yeast cloning vehicle | |
EP0220689A2 (en) | Method of using bar1 for secreting foreign proteins | |
AU660172B2 (en) | BAR1 secretion signal | |
WO1986000638A1 (en) | Yeast cloning vehicle | |
KR100246932B1 (en) | Novel Yeast Strain defected YAP3 gene and recombinamt human parathy roid hormone therefrom | |
DE69616276T2 (en) | PROCESS FOR PRODUCING PROTEINS | |
EP0245479B1 (en) | Shortened phosphoglycerate kinase promoter | |
EP0192679A1 (en) | Yeast cloning vehicles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19860728 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BERNSTINE, EDWARD, G. 4 LONGFELLOW PLACE Inventor name: LEMONTT, JEFFREY, F. Inventor name: BECK, ANTON, K. Inventor name: THILL, GREGORY, P. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19880418 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19880627 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BERNSTINE, EDWARD, G.4 LONGFELLOW PLACE Inventor name: LEMONTT, JEFFREY, F. Inventor name: THILL, GREGORY, P. Inventor name: BECK, ANTON, K. |